NASDAQ:IMNM Immunome (IMNM) Stock Price, News & Analysis $6.26 -0.47 (-6.98%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$6.30 +0.04 (+0.56%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunome Stock (NASDAQ:IMNM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunome alerts:Sign Up Key Stats Today's Range$6.19▼$6.8950-Day Range$6.26▼$11.8352-Week Range$6.19▼$22.26Volume1.20 million shsAverage Volume873,311 shsMarket Capitalization$544.31 millionP/E RatioN/ADividend YieldN/APrice Target$25.50Consensus RatingBuy Company OverviewImmunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Read More… Remove Ads Immunome Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreIMNM MarketRank™: Immunome scored higher than 42% of companies evaluated by MarketBeat, and ranked 685th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunome has only been the subject of 4 research reports in the past 90 days.Read more about Immunome's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunome are expected to decrease in the coming year, from ($2.21) to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunome is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunome is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunome has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immunome's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.59% of the float of Immunome has been sold short.Short Interest Ratio / Days to CoverImmunome has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Immunome has recently increased by 2.37%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunome does not currently pay a dividend.Dividend GrowthImmunome does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.59% of the float of Immunome has been sold short.Short Interest Ratio / Days to CoverImmunome has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Immunome has recently increased by 2.37%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.98 News SentimentImmunome has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Immunome this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for IMNM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows29 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is an increase of 222% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,322,995.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Immunome is held by insiders.Percentage Held by Institutions44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunome's insider trading history. Receive IMNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNM Stock News HeadlinesInsider Buying: Immunome, Inc. (NASDAQ:IMNM) CEO Purchases 137,100 Shares of StockMarch 27, 2025 | insidertrades.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Buys 7,000 Shares of StockMarch 26, 2025 | insidertrades.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.April 2, 2025 | Altimetry (Ad)Immunome (NASDAQ:IMNM) Trading Up 4.4% After Insider Buying ActivityMarch 28, 2025 | americanbankingnews.comImmunome CEO buys $999.5K in common stockMarch 28, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying ActivityMarch 27, 2025 | americanbankingnews.comImmunome CTO buys $103.6K in common stockMarch 26, 2025 | markets.businessinsider.comImmunome (IMNM) to Release Quarterly Earnings on ThursdayMarch 25, 2025 | americanbankingnews.comSee More Headlines IMNM Stock Analysis - Frequently Asked Questions How have IMNM shares performed this year? Immunome's stock was trading at $10.62 on January 1st, 2025. Since then, IMNM shares have decreased by 41.1% and is now trading at $6.26. View the best growth stocks for 2025 here. How were Immunome's earnings last quarter? Immunome, Inc. (NASDAQ:IMNM) issued its quarterly earnings results on Wednesday, March, 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.16. The business earned $2.74 million during the quarter, compared to analysts' expectations of $3.07 million. Immunome had a negative trailing twelve-month return on equity of 48.63% and a negative net margin of 3,014.59%. When did Immunome IPO? Immunome (IMNM) raised $30 million in an initial public offering on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO. How do I buy shares of Immunome? Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunome own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings3/19/2025Today4/02/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNM CIK1472012 Webimmunome.com Phone610-321-3700FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$25.50 High Stock Price Target$33.00 Low Stock Price Target$20.00 Potential Upside/Downside+307.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,810,000.00 Net Margins-3,014.59% Pretax Margin-3,014.59% Return on Equity-48.63% Return on Assets-41.62% Debt Debt-to-Equity RatioN/A Current Ratio6.17 Quick Ratio6.17 Sales & Book Value Annual Sales$9.04 million Price / Sales60.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book2.26Miscellaneous Outstanding Shares86,951,000Free Float72,916,000Market Cap$544.31 million OptionableOptionable Beta1.93 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:IMNM) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.